Evitar

Drug Profile

Evitar

Alternative Names: Dipeptide - AdeTherapeutics; Fibrosis prevention dipeptide - AdeTherapeutics

Latest Information Update: 14 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Saskatchewan
  • Developer AdeTherapeutics; Dalton Pharma Services; DSM
  • Class Antifibrotics; Dipeptides
  • Mechanism of Action Cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Fibrosis; Post-surgical adhesions

Most Recent Events

  • 23 Apr 2013 Evitar is available for licensing. http://www.adetherapeutics.com
  • 23 Apr 2013 Early research in Fibrosis (dermal scars) in Canada (Topical)
  • 23 Apr 2013 Phase-II clinical trials in Post-surgical adhesions in Canada (Intra-abdominal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top